OBJECTIVE: Oral anticoagulation therapy (OAT) with warfarin increases mortality and disability after intracerebral hemorrhage (ICH), the result of increased ICH volume and risk of hematoma expansion. We investigated whether OAT also influences risk of development of intraventricular hemorrhage (IVH), the volume of IVH and IVH expansion, and whether IVH is a substantive mediator of the overall effect of OAT on ICH outcome. METHODS: We performed a retrospective analysis of a prospectively collected single-center cohort of 1,879 consecutive ICH cases (796 lobar, 865 deep, 153 cerebellar, 15 multiple location, 50 primary IVH) from 1999 to 2009. ICH and IVH volumes at presentation, as well as hematoma expansion (>33% or >6 mL increase) and IVH expansion (>2 mL increase), were determined using established semiautomated methods. Outcome was assessed at 90 days using either the modified Rankin Scale or Glasgow Outcome Scale. RESULTS: Warfarin use was associated with IVH risk, IVH volume at presentation, and IVH expansion in both lobar and deep ICH (all p < 0.05) in a dose-response relationship with international normalized ratio. Warfarin was associated with poor outcome in both lobar and deep ICH (p < 0.01), and >95% of this effect was accounted for by baseline ICH and IVH volumes, as well as ICH and IVH expansion. CONCLUSION: Warfarin increases IVH volume and risk of IVH expansion in lobar and deep ICH. These findings (along with effects on ICH volume and expansion) likely represent the mechanisms by which anticoagulation worsens ICH functional outcome.
OBJECTIVE: Oral anticoagulation therapy (OAT) with warfarin increases mortality and disability after intracerebral hemorrhage (ICH), the result of increased ICH volume and risk of hematoma expansion. We investigated whether OAT also influences risk of development of intraventricular hemorrhage (IVH), the volume of IVH and IVH expansion, and whether IVH is a substantive mediator of the overall effect of OAT on ICH outcome. METHODS: We performed a retrospective analysis of a prospectively collected single-center cohort of 1,879 consecutive ICH cases (796 lobar, 865 deep, 153 cerebellar, 15 multiple location, 50 primary IVH) from 1999 to 2009. ICH and IVH volumes at presentation, as well as hematoma expansion (>33% or >6 mL increase) and IVH expansion (>2 mL increase), were determined using established semiautomated methods. Outcome was assessed at 90 days using either the modified Rankin Scale or Glasgow Outcome Scale. RESULTS:Warfarin use was associated with IVH risk, IVH volume at presentation, and IVH expansion in both lobar and deep ICH (all p < 0.05) in a dose-response relationship with international normalized ratio. Warfarin was associated with poor outcome in both lobar and deep ICH (p < 0.01), and >95% of this effect was accounted for by baseline ICH and IVH volumes, as well as ICH and IVH expansion. CONCLUSION:Warfarin increases IVH volume and risk of IVH expansion in lobar and deep ICH. These findings (along with effects on ICH volume and expansion) likely represent the mechanisms by which anticoagulation worsens ICH functional outcome.
Authors: B B Thompson; Y Béjot; V Caso; J Castillo; H Christensen; M L Flaherty; C Foerch; K Ghandehari; M Giroud; S M Greenberg; H Hallevi; J C Hemphill; P Heuschmann; S Juvela; K Kimura; P K Myint; Y Nagakane; H Naritomi; S Passero; M R Rodríguez-Yáñez; J Roquer; J Rosand; N S Rost; P Saloheimo; V Salomaa; J Sivenius; T Sorimachi; M Togha; K Toyoda; W Turaj; K N Vemmos; C D A Wolfe; D Woo; E E Smith Journal: Neurology Date: 2010-09-08 Impact factor: 9.910
Authors: Alexander Y Zubkov; Jayawant N Mandrekar; Daniel O Claassen; Edward M Manno; Eelco F M Wijdicks; Alejandro A Rabinstein Journal: Arch Neurol Date: 2008-10
Authors: Charlotte Jj van Asch; Merel Ja Luitse; Gabriël Je Rinkel; Ingeborg van der Tweel; Ale Algra; Catharina Jm Klijn Journal: Lancet Neurol Date: 2010-01-05 Impact factor: 44.182
Authors: M L Flaherty; H Tao; M Haverbusch; P Sekar; D Kleindorfer; B Kissela; P Khatri; B Stettler; O Adeoye; C J Moomaw; J P Broderick; D Woo Journal: Neurology Date: 2008-09-30 Impact factor: 9.910
Authors: Emilie FitzMaurice; Lauren Wendell; Ryan Snider; Kristin Schwab; Rishi Chanderraj; Cathrine Kinnecom; Kaveer Nandigam; Natalia S Rost; Anand Viswanathan; Jonathan Rosand; Steven M Greenberg; Eric E Smith Journal: Stroke Date: 2008-04-24 Impact factor: 7.914
Authors: D Andrew Wilkinson; Aditya S Pandey; B Gregory Thompson; Richard F Keep; Ya Hua; Guohua Xi Journal: Neuropharmacology Date: 2017-09-22 Impact factor: 5.250
Authors: Guido J Falcone; H Bart Brouwers; Alessandro Biffi; Christopher D Anderson; Thomas W K Battey; Alison M Ayres; Anastasia Vashkevich; Kristin M Schwab; Natalia S Rost; Joshua N Goldstein; Anand Viswanathan; Steven M Greenberg; Jonathan Rosand Journal: Neurocrit Care Date: 2014-10 Impact factor: 3.210
Authors: Sandro Marini; William J Devan; Farid Radmanesh; Laura Miyares; Timothy Poterba; Björn M Hansen; Bo Norrving; Jordi Jimenez-Conde; Eva Giralt-Steinhauer; Roberto Elosua; Elisa Cuadrado-Godia; Carolina Soriano; Jaume Roquer; Christina E Kourkoulis; Alison M Ayres; Kristin Schwab; David L Tirschwell; Magdy Selim; Devin L Brown; Scott L Silliman; Bradford B Worrall; James F Meschia; Chelsea S Kidwell; Joan Montaner; Israel Fernandez-Cadenas; Pilar Delgado; Steven M Greenberg; Arne Lindgren; Charles Matouk; Kevin N Sheth; Daniel Woo; Christopher D Anderson; Jonathan Rosand; Guido J Falcone Journal: Stroke Date: 2018-06-18 Impact factor: 7.914